Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Tuesday, Incyte Corporation INCY agreed to acquire Escient Pharmaceuticals for $750 million. Escient’s pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), and EP547, a first-in-class oral MRGPRX4 …